Filtros de búsqueda

Lista de obras de Stanley B Cohen

2012 challenges in rheumatoid arthritis care

artículo científico publicado en 2012

A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy of Oral SCIO-469, a p38 Mitogen-activated Protein Kinase Inhibitor, in Patients with Active Rheumatoid Arthritis ⬇️

artículo científico publicado el 1 de febrero de 2011

A Phase 1 Dose-Escalation Study of ASP2409, a Selective T-Cell Costimulation Inhibitor, in Stable Rheumatoid Arthritis Patients on Methotrexate Therapy

artículo científico

A Randomized, Double-Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis

artículo científico publicado en 2020

A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca

artículo científico publicado en 2002

A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis ⬇️

artículo científico publicado en 2016

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

scientific article published on 17 October 2011

A pilot study of rituximab in immune-mediated inner ear disease

scientific article published on 27 October 2010

A pooled analysis of the safety of tofacitinib as monotherapy or in combination with background conventional synthetic disease-modifying antirheumatic drugs in a Phase 3 rheumatoid arthritis population

artículo científico publicado en 2018

A randomised, double-blind trial to demonstrate bioequivalence of GP2013 and reference rituximab combined with methotrexate in patients with active rheumatoid arthritis

artículo científico publicado en 2017

A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.

artículo científico publicado en 2018

A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the knee

artículo científico publicado en 2011

Allele and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase 1 trial

artículo científico publicado en 2003

American College of Rheumatology Guidance for the Management of Adult Patients with Rheumatic Disease During the COVID-19 Pandemic

artículo científico publicado en 2020

American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2

artículo científico publicado en 2020

American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 3

artículo científico publicado en 2020

An Extension Study of PF-05280586, a Potential Rituximab Biosimilar, versus Rituximab in Subjects with Active Rheumatoid Arthritis.

artículo científico publicado en 2018

An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis

scientific article published on 29 March 2019

An update on bisphosphonates

artículo científico publicado en 2004

Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis

artículo científico publicado en 2014

Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept

artículo científico publicado en 2016

Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies

scientific article published on 15 October 2020

B-cell depletion for rheumatic diseases: where are we?

artículo científico publicado en 2005

Biosimilars: implications for rheumatoid arthritis therapy

artículo científico publicado en 2017

Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus Erythematosus.

artículo científico publicado en 2016

Brief Report: A Phase IIb Trial of a Novel Extended-Release Microsphere Formulation of Triamcinolone Acetonide for Intraarticular Injection in Knee Osteoarthritis. ⬇️

artículo científico publicado en 2017

Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment

artículo científico publicado en 2010

Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate

artículo científico publicado en 2004

Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis

scientific article published on 26 March 2020

Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept.

artículo científico publicado en 2006

Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate

artículo científico publicado en 2010

Correction to: Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis

scientific article published on 23 September 2020

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion

article

Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial

scientific article published on 27 March 2019

Denosumab in postmenopausal women with low bone mineral density

artículo científico publicado en 2006

Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial

article

Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis

artículo científico publicado en 2018

Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis

artículo científico publicado en 2012

Effects of a Single Intra-Articular Injection of a Microsphere Formulation of Triamcinolone Acetonide on Knee Osteoarthritis Pain: A Double-Blinded, Randomized, Placebo-Controlled, Multinational Study. ⬇️

artículo científico publicado en 2018

Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates

artículo científico publicado en 2009

Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy.

artículo científico publicado en 2005

Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus

artículo científico publicado en 2004

Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials

artículo científico publicado en 2016

Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial

artículo científico publicado en 2020

Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial

artículo científico publicado en 2010

Efficacy and safety of rofecoxib 12.5 mg versus nabumetone 1,000 mg in patients with osteoarthritis of the knee: a randomized controlled trial

artículo científico publicado en 2004

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study

artículo científico publicado en 2017

Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III.

artículo científico publicado en 2015

Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study

artículo científico publicado en 2005

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

artículo científico publicado en 2004

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis

artículo científico publicado en 2009

Extremity magnetic resonance imaging in rheumatoid arthritis: Updated literature review

artículo científico publicado en 2011

Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study)

scientific article published on 09 April 2020

Glucocorticoids and osteoporosis: predicting fracture risk ⬇️

artículo científico publicado el 1 de diciembre de 2010

Immune-mediated inner ear disease: 10-year experience

artículo científico publicado en 2004

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data

scientific article published on 05 August 2020

Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis.

artículo científico publicado en 2003

JAK Inhibitors: What Is New?

scientific article published on 22 July 2020

Kinase inhibitors: a new approach to rheumatoid arthritis treatment

artículo científico publicado en 2010

Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Doub

scientific article published on 01 April 2020

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.

artículo científico publicado en 2017

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

artículo científico publicado en 2020

Long-term safety, efficacy, and immunogenicity of adalimumab biosimilar BI 695501 and adalimumab reference product in patients with moderately-to-severely active rheumatoid arthritis: results from a phase 3b extension study (VOLTAIRE-RAext)

artículo científico publicado en 2019

Malignancy and Janus Kinase Inhibition

artículo científico publicado en 2017

Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5-year data from the REFLEX study

artículo científico publicado en 2012

Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.

artículo científico publicado en 2009

Outcomes of infliximab dose escalation in patients with rheumatoid arthritis

scientific article published on 02 May 2019

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis

artículo científico publicado en 2007

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients

artículo científico publicado en 2016

Randomised, double-blind, phase III study comparing the infliximab biosimilar, PF-06438179/GP1111, with reference infliximab: efficacy, safety and immunogenicity from week 30 to week 54

artículo científico publicado en 2019

Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis

artículo científico publicado en 2020

Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies

artículo científico publicado en 2005

Rheumatoid arthritis: Threshold for success in RA drug development

artículo científico publicado en 2012

Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthri

artículo científico publicado en 2006

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

artículo científico publicado en 2006

Role of RANK ligand in normal and pathologic bone remodeling and the therapeutic potential of novel inhibitory molecules in musculoskeletal diseases

artículo científico publicado en 2006

Safety and Immunogenicity of Rituximab Biosimilar GP2013 After Switch from Reference Rituximab in Patients with Active Rheumatoid Arthritis

artículo científico publicado en 2019

Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

scholarly article by Jürgen Wollenhaupt et al published 5 April 2019 in Arthritis Research and Therapy

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme

scientific article published on 28 October 2020

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus

artículo científico

Scientific rationale underpinning the development of biosimilar rituximab in hematological cancers and inflammatory diseases

artículo científico publicado en 2019

Similar efficacy, safety and immunogenicity of adalimumab biosimilar BI 695501 and Humira reference product in patients with moderately to severely active rheumatoid arthritis: results from the phase III randomised VOLTAIRE-RA equivalence study.

artículo científico publicado en 2018

Small molecular therapies for rheumatoid arthritis: where do we stand?

artículo científico publicado en 2011

Successful administration of BI 695501, an adalimumab biosimilar, using an autoinjector (AI): results from a Phase II open-label clinical study (VOLTAIRE®-RL).

artículo científico publicado en 2018

Targeting the B Cell in Rheumatoid Arthritis ⬇️

artículo científico publicado el 1 de agosto de 2010

The 2008 American College of Rheumatology recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis: where the rubber meets the road

artículo científico publicado en 2008

The American College of Rheumatology/European League Against Rheumatism Criteria for the classification of rheumatoid arthritis: a game changer

artículo científico publicado en 2010

The American College of Rheumatology/European League Against Rheumatism criteria for the classification of rheumatoid arthritis: A game changer ⬇️

artículo científico publicado el 1 de septiembre de 2010

The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had

scientific article published on 01 January 2006

The Science Behind Biosimilars: Entering a New Era of Biologic Therapy

artículo científico publicado en 2018

The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis

artículo científico publicado en 2004

The evolving use of tumor necrosis factor inhibitors in rheumatoid arthritis

scientific article published on 01 October 2004

The use of anakinra, an interleukin-1 receptor antagonist, in the treatment of rheumatoid arthritis

artículo científico publicado en 2004

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study

artículo científico publicado en 2013

Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study

scientific article published on 24 April 2019

Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study

scientific article published on 19 December 2019

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

article

Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate

scientific article published on 03 July 2018

Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial

artículo científico publicado en 2002

Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort

artículo científico publicado en 2008

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

artículo científico publicado en 2007

Underuse of Methotrexate in the Treatment of Rheumatoid Arthritis: A National Analysis of Prescribing Practices in the US.

artículo científico publicado en 2016

Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence.

artículo científico publicado en 2008

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study

artículo científico publicado en 2019

Updates from B Cell Trials: Efficacy.

artículo científico publicado en 2006

Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial

artículo científico publicado en 2005

Why the ACR? ⬇️

artículo científico publicado el 1 de febrero de 2011

Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis.

artículo científico publicado en 2018

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda